Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.
Herrmann K, Gafita A, de Bono JS, Sartor O, Chi KN, Krause BJ, Rahbar K, Tagawa ST, Czernin J, El-Haddad G, Wong CC, Zhang Z, Wilke C, Mirante O, Morris MJ, Fizazi K. Herrmann K, et al. Among authors: gafita a. EClinicalMedicine. 2024 Oct 4;77:102862. doi: 10.1016/j.eclinm.2024.102862. eCollection 2024 Nov. EClinicalMedicine. 2024. PMID: 39430616 Free PMC article.
Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.
Nikitas J, Gafita A, Benz MR, Djaïleb L, Farolfi A, Hotta M, Sonni I, Alano R, Rettig M, Shen J, Armstrong W, Grogan T, Liu S, Czernin J, Calais J. Nikitas J, et al. Among authors: gafita a. Sci Rep. 2024 Oct 18;14(1):24411. doi: 10.1038/s41598-024-75589-6. Sci Rep. 2024. PMID: 39420060 Free PMC article. Clinical Trial.
Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.
Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Tuchayi AM, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J, Gafita A. Murthy V, et al. Among authors: gafita a. J Nucl Med. 2024 Sep 26:jnumed.124.267816. doi: 10.2967/jnumed.124.267816. Online ahead of print. J Nucl Med. 2024. PMID: 39327018
Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
Gafita A, Voter A, Shesadri S, Spitz A, Marshall CH, Rowe SP, Markwoski MC, Pomper MG, Civelek AC, Carducci MA, Denmeade SR, Young J, Pienta KJ, Paller CJ, Solnes LB. Gafita A, et al. J Nucl Med. 2024 Sep 19:jnumed.124.267723. doi: 10.2967/jnumed.124.267723. Online ahead of print. J Nucl Med. 2024. PMID: 39299783
Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics.
Xue S, Gafita A, Zhao Y, Mercolli L, Cheng F, Rauscher I, D'Alessandria C, Seifert R, Afshar-Oromieh A, Rominger A, Eiber M, Shi K. Xue S, et al. Among authors: gafita a. Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3450-3460. doi: 10.1007/s00259-024-06737-3. Epub 2024 May 9. Eur J Nucl Med Mol Imaging. 2024. PMID: 38724653 Free PMC article.
70 results